scholarly journals Extended use of brentuximab vedotin before autologous stem-cell transplantation would benefit refractory systemic anaplastic large-cell lymphoma

2018 ◽  
Vol 6 (5) ◽  
pp. 798-801
Author(s):  
Youngil Koh
2021 ◽  
Vol 14 (2) ◽  
pp. e239213
Author(s):  
Nabin Raj Karki ◽  
Kristine Badin ◽  
Natasha Savage ◽  
Locke Bryan

Anaplastic large cell lymphoma (ALCL), ALK negative (ALK−) is an aggressive lymphoproliferative disorder of mature T lymphocytes characterised by hallmark cells, CD30 positivity and lacking ALK protein expression. ALCL, ALK− has to be differentiated from peripheral T-cell lymphoma-not otherwise specified and classical Hodgkin’s lymphoma. ALK− anaplastic large cell leukaemia should be considered in a patient with a history of ALCL, ALK− presenting with new leukaemia. We report a rare presentation of relapsed ALCL, ALK− with leukaemia after autologous stem cell transplantation in a 57-year-old male. Leukaemia, either as primary presentation or secondary transformation confers worse prognosis in ALCL, ALK− with very few cases reported so far. Emergency resuscitation with leukapheresis and treatment of tumour lysis syndrome along with supportive care should be followed by combination chemotherapy. Brentuximab vedotin and stem cell transplantation are the backbone of treatment for relapsed/refractory disease.


2006 ◽  
Vol 12 (6) ◽  
pp. 641-647 ◽  
Author(s):  
Amrita Krishnan ◽  
Auayporn Nademanee ◽  
Henry Fung ◽  
Maria Angelopoulou ◽  
Arturo Molina ◽  
...  

2008 ◽  
Vol 26 (3) ◽  
pp. 171-178 ◽  
Author(s):  
José Rodríguez ◽  
Eulogio Conde ◽  
Antonio Gutiérrez ◽  
Juan Carlos García ◽  
Juan José Lahuerta ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document